Comprehensive analysis of antibody recognition in convalescent humans from highly pathogenic avian influenza H5N1 infection

Nature Communications

Volumn 6, Issue , 2015, Pages

  Zuo, Teng ^a   Sun, Jianfeng ^b,c   Wang, Guiqin ^d   Jiang, Liwei ^a   Zuo, Yanan ^a   Li, Danyang ^a   Shi, Xuanling ^a   Liu, Xi ^b,c   Fan, Shilong ^b   Ren, Huanhuan ^d   Hu, Hongxing ^d   Sun, Lina ^e   Zhou, Boping ^f   Liang, Mifang ^e   Zhou, Paul ^d   Wang, Xinquan ^b,c   Zhang, Linqi ^a  

^a Tsinghua University   (China)

^b TSINGHUA UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

^d INSTITUTE PASTEUR OF SHANGHAI   (China)

^e National Institute for Viral Disease Control and Prevention   (China)

^f SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEMAGGLUTININ; HUMAN MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ANTIBODY; BIRD; BLOOD; CRYSTAL STRUCTURE; GENE EXPRESSION; IMMUNE RESPONSE; INFLUENZA; MUTATION; VACCINE; VULNERABILITY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; AVIAN INFLUENZA; CASE REPORT; COMPLEMENTARITY DETERMINING REGION; CONVALESCENCE; CRYSTAL STRUCTURE; EPITOPE MAPPING; FEMALE; HEAVY CHAIN; HUMAN; INFLUENZA A (H5N1); MALE; MEMORY CELL; NONHUMAN; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; ANIMAL; BIRD; CHEMISTRY; GENETICS; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H5N1); PATHOGENICITY; PROTEIN TERTIARY STRUCTURE; VIROLOGY; VIRULENCE;

AVES; INFLUENZA A VIRUS;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BIRDS; EPITOPE MAPPING; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; MALE; PROTEIN STRUCTURE, TERTIARY; VIRULENCE;

EID: 84949310072     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9855     Document Type: Article

References (63)

1. Fauci, A. S. Emerging and re-emerging infectious diseases: influenza as a prototype of the host-pathogen balancing act. Cell 124, 665-670 (2006).
2. Park, A. W. & Glass, K. Dynamic patterns of avian and human influenza in east and southeast Asia. Lancet Infect. Dis. 7, 543-548 (2007).
3. Salomon, R. & Webster, R. G. The influenza virus enigma. Cell 136, 402-410 (2009).
4. Xu, X., Subbarao, K., Cox, N. J. & Guo, Y. Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 261, 15-19 (1999).
5. Li, Y. et al. Continued evolution of H5N1 influenza viruses in wild birds, domestic poultry, and humans in China from 2004 to 2009. J. Virol. 84, 8389-8397 (2010).
6. Smith, G. J. et al. Emergence and predominance of an H5N1 influenza variant in China. Proc. Natl Acad. Sci. USA 103, 16936-16941 (2006).
7. Wan, X. F. et al. Indications that live poultry markets are a major source of human H5N1 influenza virus infection in China. J. Virol. 85, 13432-13438 (2011).
8. Chen, H. et al. Avian flu: H5N1 virus outbreak in migratory waterfowl. Nature 436, 191-192 (2005).
9. Liu, J. et al. Highly pathogenic H5N1 influenza virus infection in migratory birds. Science 309, 1206 (2005).
10. Claas, E. C. et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351, 472-477 (1998).
11. Cowling, B. J. et al. Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases. Lancet 382, 129-137 (2013).
12. Yu, H. et al. Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS ONE 3, e2985 (2008).
13. Russell, C. J. & Webster, R. G. The genesis of a pandemic influenza virus. Cell 123, 368-371 (2005).
14. Wang, H. et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 371, 1427-1434 (2008).
15. Herfst, S. et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336, 1534-1541 (2012).
16. Imai, M. et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486, 420-428 (2012).
17. Zhang, Y. et al. H5N1 hybrid viruses bearing 2009/H1N1 virus genes transmit in guinea pigs by respiratory droplet. Science 340, 1459-1463 (2013).
18. Group., W.O.F.H.N.E.W. Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature. Influenza Other Respir. Viruses 6, 1-5 (2011).
19. Li, K. S. et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430, 209-213 (2004).
20. Nicholls, J. M. et al. Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat. Med. 13, 147-149 (2007).
21. Caton, A. J., Brownlee, G. G., Yewdell, J. W. & Gerhard, W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31, 417-427 (1982).
22. Gerhard, W., Yewdell, J., Frankel, M. E. & Webster, R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290, 713-717 (1981).
23. Wiley, D. C., Wilson, I. A. & Skehel, J. J. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289, 373-378, 1981
24. Wilson, I. A., Skehel, J. J. & Wiley, D. C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3A resolution. Nature 289, 366-373 (1981).
25. Chiu, C., Ellebedy, A. H., Wrammert, J. & Ahmed, R. B Cell Responses to Influenza Infection and Vaccination. Curr. Top Microbiol. Immunol. 386, 381-398 (2014).
26. Li, C. K., Rappuoli, R. & Xu, X. N. Correlates of protection against influenza infection in humans-on the path to a universal vaccine? Curr. Opin. Immunol. 25, 470-476 (2013).
27. Pica, N. & Palese, P. Toward a universal influenza virus vaccine: prospects and challenges. Annu. Rev. Med. 64, 189-202 (2013).
28. Lingwood, D. et al. Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489, 566-570 (2012).
29. Li, Y. et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J. Exp. Med. 210, 1493-1500 (2013).
30. Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181-193 (2011).
31. Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667-671 (2008).
32. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
33. Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251 (2009).
34. Ekiert, D. C. et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843-850 (2011).
35. Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265-273 (2009).
36. Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343-1348 (2012).
37. Hu, H. et al. A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. J. Virol. 86, 2978-2989 (2012).
38. Sun, L. et al. Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS ONE 4, e5476 (2009).
39. Zhou, B. P., Zhong, N. S. & Guan, Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N. Engl. J. Med. 357, 1450-1451 (2007).
40. Zuo, T. et al. Comprehensive analysis of pathogen-specific antibody response in vivo based on an antigen library displayed on surface of yeast. J. Biol. Chem. 286, 33511-33519 (2011).
41. Shore, D. A. et al. Structural and Antigenic Variation among Diverse Clade 2 H5N1 Viruses. PLoS ONE 8, e75209 (2013).
42. Qian, M. et al. Unraveling of a neutralization mechanism by two human antibodies against conserved epitopes in the globular head of H5 hemagglutinin. J. Virol. 87, 3571-3577 (2013).
43. Zhu, X. et al. A unique and conserved neutralization epitope in H5N1 influenza viruses identified by an antibody against the A/Goose/Guangdong/1/96 hemagglutinin. J. Virol. 87, 12619-12635 (2013).
44. Wang, T. T. et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl Acad. Sci. USA 107, 18979-18984 (2010).
45. Wang, G. et al. DNA prime and virus-like particle boost from a single H5N1 strain elicits broadly neutralizing antibody responses against head region of H5 hemagglutinin. J. Infect. Dis. 209, 676-685 (2014).
46. Chiu, C. et al. Cross-reactive humoral responses to influenza and their implications for a universal vaccine. Ann. NY Acad. Sci. 1283, 13-21 (2013).
47. Xu, R. et al. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328, 357-360 (2010).
48. Ekiert, D. C. et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489, 526-532 (2012).
49. Whittle, J. R. et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl Acad. Sci. USA 108, 14216-14221 (2011).
50. Lee, P. S. et al. Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc. Natl Acad. Sci. USA 109, 17040-17045 (2012).
51. DiazGranados, C. A. et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N. Engl. J. Med. 371, 635-645 (2014).
52. Fiore, A. E., Bridges, C. B. & Cox, N. J. Seasonal influenza vaccines. Curr. Top Microbiol. Immunol. 333, 43-82 (2009).
53. Khurana, S. et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2, 15ra15 (2010).
54. Khurana, S. et al. MF59 adjuvant enhances diversity and affinity of antibodymediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3, 85ra48 (2011).
55. Khurana, S. et al. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci. Transl. Med. 5, 200ra114 (2013).
56. Song, L. et al. Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 27, 5875-5884 (2009).
57. Verma, S. et al. Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies. J. Virol. 86, 12283-12293 (2012).
58. Xuan, C. et al. Structural vaccinology: structure-based design of influenza A virus hemagglutinin subtype-specific subunit vaccines. Protein Cell 2, 997-1005 (2011).
59. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Macromol. Crystallogr. A 276, 307-326 (1997).
60. McCoy, A. J. Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr. Sect. D-Biol. Crystallogr. 63, 32-41 (2007).
61. Adams, P. D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. Sect. D-Biol. Crystallogr. 58, 1948-1954 (2002).
62. Laskowski, R. A., Macarthur, M. W., Moss, D. S. & Thornton, J. M. Procheck - a Program to Check the Stereochemical Quality of Protein Structures. J. Appl. Crystallogr. 26, 283-291 (1993).
63. Delano, W. L. Pymol Molecular Graphics System. http://pymol.org/ (2002).